l9ls
mAbexperimental
Clinical trial activity
7 trials · 12 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Mar 18, 2022 (NCT05304611)
Timeline
Indications
Mechanism of action
- Plasmodium vivaxINHIBITOR
Plasmodium vivax inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07208760 | Phase 2 | Nov 30, 2025 | Indiana University, Malaria Research and Training Center, Bamako, Mali, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), University of Washington |
| NCT07060508 | Phase 2 | Jul 22, 2025 | Harvard University, Indiana University, Malaria Research and Training Center, Bamako, Mali, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), University of the Sciences, Techniques and Technologies of Bamako, University of Washington |
| NCT07082205 | Phase 3 | May 2, 2025 | Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID), University of Liverpool |
| NCT06461026 | Phase 1 | Aug 19, 2024 | Harvard University, Indiana University, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), University of Washington |
| NCT05816330 | Phase 2 | May 25, 2023 | Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS/FAPH), Faculté de Médecine Pharmacie d'Odontostomatologie (FMPOS), Harvard University, Indiana University, Malaria Research and Training Center, Bamako, Mali, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), University of the Sciences, Techniques and Technologies of Bamako, University of Washington |
| NCT05400655 | Phase 2 | Sep 14, 2022 | Centers for Disease Control and Prevention (CDC), Kenya Medical Research Institute, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), University of Liverpool |
| NCT05304611 | Phase 2 | Mar 18, 2022 | Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS/FAPH), Faculté de Médecine Pharmacie d'Odontostomatologie (FMPOS), Harvard University, Indiana University, Malaria Research and Training Center, Bamako, Mali, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), University of the Sciences, Techniques and Technologies of Bamako, University of Washington |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (12)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 7 | 6 | 3 | 2022 |
| National Institutes of Health (NIH) | Government | 6 | 0 | 2 | 2022 |
| Indiana University | Academic/Hospital | 5 | 0 | 2 | 2022 |
| University of Washington | Academic/Hospital | 5 | 0 | 2 | 2022 |
| Harvard University | Academic/Hospital | 4 | 0 | 2 | 2022 |
| Malaria Research and Training Center, Bamako, Mali | Academic/Hospital | 4 | 0 | 1 | 2022 |
| University of the Sciences, Techniques and Technologies of Bamako | Academic/Hospital | 3 | 0 | 1 | 2022 |
| Centers for Disease Control and Prevention (CDC) | Government | 2 | 0 | 2 | 2022 |
| Faculté de Médecine Pharmacie d'Odontostomatologie (FMOS/FAPH) | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Faculté de Médecine Pharmacie d'Odontostomatologie (FMPOS) | Academic/Hospital | 2 | 0 | 1 | 2022 |
| University of Liverpool | Academic/Hospital | 2 | 1 | 2 | 2022 |
| Kenya Medical Research Institute | Academic/Hospital | 1 | 0 | 1 | 2022 |
12 organizations
Page 1 / 1